Abstract
ObjectivesAdherence is key to the effectiveness of oral pre-exposure prophylaxis (PrEP) to prevent HIV. Therefore, we aimed to explore factors associated with adherence to daily PrEP (dPrEP).MethodsMen who have sex with men (MSM) using dPrEP (emtricitabine/tenofovir disoproxil) within the Amsterdam PrEP demonstration project at the Public Health Service of Amsterdam, provided dried blood spots (DBS) 12 and 24 months after PrEP initiation. From DBS, we determined intracellular tenofovir diphosphate (TFV-DP) concentrations to assess adherence; TFV-DP ≥700 fmol/punch was considered adequate. We assessed associations of sociodemographic, clinical and behavioural characteristics with TFV-DP concentrations using multivariable linear regression.ResultsOf 263 participants who attended 12-month or 24-month study visits while on dPrEP, 257 (97.7%) provided DBS at one or both visits (492 DBS in total). Median TFV-DP concentration was 1299 (IQR 1021–1627) fmol/punch (12 months: 1332 (1087–1687); 24 months: 1248 (929–1590]). Higher TFV-DP concentrations were associated with: older age (p=0.0008), condomless anal sex with a casual partner in 6 months preceding PrEP initiation (+166 fmol/punch; 95% CI 36.5 to 296) and using a mobile application providing visualised feedback on PrEP use and sexual behaviour (+146 fmol/punch; 95% CI 28.1 to 263). Lower TFV-DP concentrations were associated with longer duration of PrEP use (24 vs 12 months; −91.5 fmol/punch; 95% CI −155 to −28.1). Time-updated number of sex partners, diagnosed STIs and chemsex were not associated with TFV-DP concentrations.ConclusionsOverall, TFV-DP concentrations were high among MSM using dPrEP, indicating excellent adherence. Especially older participants, those who reported condomless anal sex with a casual partner prior to PrEP initiation and those who used an app with visualised feedback showed higher levels of adherence. As TFV-DP concentrations had decreased slightly at 2 years of PrEP use when compared with 1 year, we emphasise the importance of adherence counselling to those who continue using PrEP.Trial registration numberNL5413.
Funder
ViiV Healthcare
Stichting Amsterdam-Dinner Foundation
M.A.C. Aids Fund
ZonMw
H-TEAM
Janssen Pharmaceuticals
Aidsfonds Netherlands
Gilead Sciences
Gilead Sciences Europe Ltd
Rijksinstituut voor Volksgezondheid en Milieu
GGD research funds
Subject
Infectious Diseases,Dermatology
Reference30 articles.
1. van Sighem AI , FWNM W , Boyd A , Smit C , Matser A , van der Valk M . Monitoring report 2021. Human immunodeficiency virus (HIV) infection in the Netherlands. Amsterdam Stichting hiv monitoring; 2021.
2. Preparing for the unexpected: mechanisms and management of HIV pre-exposure prophylaxis failure;Dashwood;Future Virol,2018
3. WHO . WHO implementation tool for pre-exposure prophylaxis of HIV infection. Geneva, Switzerland World Health Organization; 2017.
4. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in dried blood spots following directly observed therapy;Anderson;Antimicrob Agents Chemother,2018
5. Tenofovir, Emtricitabine, and Tenofovir Diphosphate in Dried Blood Spots for Determining Recent and Cumulative Drug Exposure
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献